Primary pituitary lymphoma successfully treated with Bruton’s tyrosine kinase inhibitor monotherapy: case report

Keijiro Yoshida; Tomonari Suzuki; Hiroki Sato; Hiroki Kobayashi; Reina Mizuno; Mitsuaki Shirahata; Tatsuya Ozawa; Kazuhiko Mishima

doi:10.55005/v3i1.7

Authors

Keijiro Yoshida Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center
Tomonari Suzuki
Hiroki Sato
Hiroki Kobayashi
Reina Mizuno
Mitsuaki Shirahata
Tatsuya Ozawa
Kazuhiko Mishima

DOI:

https://doi.org/10.55005/v3i1.7

Keywords:

hypopituitarism, malignant lymphoma, primary pituitary lymphoma, Bruton's tyrosine kinase inhibitor, tirabrutinib

Abstract

Introduction: Primary pituitary lymphoma (PPL) is a rare disease characterized by lymphoma confined to the sella or parasellar region without systemic involvement. The clinical symptoms of PPL may include headache, hypopituitarism, visual field disturbance and visual impairment. To date, there is no established standard treatment for this condition.

Here, we present a case of successful treatment with a Bruton’s tyrosine kinase (BTK) inhibitor.

Case report: A 78-years-old man with a history of severe left renal insufficiency caused by retroperitoneal fibrosis, and sequential right nephrostomy, underwent brain magnetic resonance imaging (MRI) due to the altered hormonal status. An enlarged pituitary stalk was noted and led to a diagnosis of lymphocytic hypopituitarism.

Six months later, visual field disturbance and visual acuity deterioration developed, and an MRI revealed a neoplastic lesion and further enlargement of the stalk and the pituitary itself, with an obvious optic nerve compression. Expedited transsphenoidal partial resection was performed to relieve the compression. Pathohystology led to the diagnosis of the large B-cell lymphoma of the germinal center origin. Because of the patient’s poor renal function, high-dose methotrexate therapy was not an option; rather, the patient was treated with a BTK inhibitor - tirabrutinib. Symptoms improved within a week, and a follow-up MRI confirmed a marked reduction of the pituitary lesion.

Conclusion: BTK inhibitors may be considered as a first-line treatment option for PPL, especially in patients with contraindications for other treatment protocols.

References

Giustina A, Gola M, Doga M, Rosei EA. Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity. J Clin Endocrinol Metab. 2001;86(10):4567-4575. doi:10.1210/jcem.86.10.7909

Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am. 1999;28(1):81-vi. doi:10.1016/s0889-8529(05)70058-x

Duan L, Liu J, Zhang Y, et al. Primary Pituitary Lymphoma in Immunocompetent Patients: A Report on Two Case Studies and the Review of Literature. Front Endocrinol (Lausanne). 2021;11:562850. Published 2021 Feb 4. doi:10.3389/fendo.2020.562850

Tarabay A, Cossu G, Berhouma M, Levivier M, Daniel RT, Messerer M. Primary pituitary lymphoma: an update of the literature. J Neurooncol. 2016;130(3):383-395. doi:10.1007/s11060-016-2249-z

Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122-133. doi:10.1093/neuonc/noaa145

Okita Y, Kano-Fujiwara R, Nakatsuka SI, Honma K, Kinoshita M. Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma. Exp Hematol Oncol. 2021;10(1):29. doi:10.1186/s40164-021-00222-5

Nakamura H, Takami H, Yanagisawa T, et al. The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. Neuro Oncol. 2022;24(4):503-515. doi:10.1093/neuonc/noab242

Konishi J, Miki Y, Asato R. Imaging Diagnosis of Hypothalamic Pituitary Diseases. Nihon Naika Gakkai Zasshi. 1994;83(12):2117-21. doi: 10.2169/naika.83.2117.

Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797-1807. doi:10.1038/leu.2011.169

Mahadevan A, Rao CR, Shanmugham M, Shankar SK. Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: Immunophenotypic subtypes and Epstein-Barr virus association. J Neurosci Rural Pract. 2015;6(1):8-14. doi:10.4103/0976-3147.143171

Yang XL, Liu YB. Advances in Pathobiology of Primary Central Nervous System Lymphoma. Chin Med J (Engl). 2017;130(16):1973-1979. doi:10.4103/0366-6999.211879

Zheng X, Ding N, Song Y, Feng L, Zhu J. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer Cell Int. 2014;14(1):32. Published 2014 Apr 3. doi:10.1186/1475-2867-14-32

Quintero Wolfe S, Hood B, Barker J, Benveniste RJ. Primary central nervous system lymphoma mimicking pituitary apoplexy: case report. Pituitary. 2009;12(1):76-79. doi:10.1007/s11102-008-0084-8

Rudnik A, Larysz D, Blamek S, et al. Primary pituitary lymphoma. Folia Neuropathol. 2007;45(3):144-148.

Ogawa A, Sugano H, Inoue T, Fujihara M, Matsumoto S, Tsuchiyama Y, et al. Malignant Lymphoma Presented with Thickned Pituitary Stalk and Hypopituitalism. Nihon Naika Gakkai Zasshi. 2008;97(6):1324-6. doi: 10.2169/naika.97.1324.

Huang YY, Lin SF, Dunn P, Wai YY, Hsueh C, Tsai JS. Primary pituitary lymphoma presenting as hypophysitis. Endocr J. 2005;52(5):543-549. doi:10.1507/endocrj.52.543

Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140(9):971-979. doi:10.1182/blood.2020008377

Ravindra VM, Raheja A, Corn H, et al. Primary pituitary diffuse large B-cell lymphoma with somatotroph hyperplasia and acromegaly: case report. J Neurosurg. 2017;126(5):1725-1730. doi:10.3171/2016.5.JNS16828

Romeike BF, Joellenbeck B, Stein H, et al. Precursor T-lymphoblastic lymphoma within a recurrent pituitary adenoma. Acta Neurochir (Wien). 2008;150(8):833-836. doi:10.1007/s00701-008-1585-y

Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-1047. doi:10.1016/S1470-2045(10)70229-1

Ban VS, Chaudhary BR, Allinson K, Santarius T, Kirollos RW. Concomitant Primary CNS Lymphoma and FSH-Pituitary Adenoma Arising Within the Sella. Entirely Coincidental? Neurosurgery. 2017;80(1):E170-E175. doi: 10.1093/neuros/nyw003